Needham Initiates Coverage On TransMedics Gr with Buy Rating, Announces Price Target of $208
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has initiated coverage on TransMedics Group (NASDAQ:TMDX) with a Buy rating and set a price target of $208.
August 21, 2024 | 11:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham has initiated coverage on TransMedics Group with a Buy rating and a price target of $208, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $208 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100